Alcon, Inc.

Novartis Ag

Huixiang Zhang

Wesley Wehsin Han

Ernesto J Castillo

Laman L Alani

Onkar N Singh

Haresh G Bhagat

Suresh Dixit

Joseph Paul Bullock

Alok Kulshreshtha

Li Wan

Charles Boring

Yuhong Zeng

Ronald F Berry

Glenn D Stafford, Jr

Suresh C Dixit

The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

Stable protein solution formulation containing high concentration of an anti-VEGF antibody

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.

Olopatadine formulations for topical administration

Aqueous pharmaceutical solution compositions preserved with a cationic preservative and comprising a cationic drug and a sulfonated styrene/maleic anhydride copolymer are disclosed. The compositions are particularly well suited for topical ophthalmic use, but may also be used as topically administrable otic or nasal compositions.

Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride

Growing community of inventors

Fort Worth, TX, United States of America

Huixiang Zhang